SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: EZLibra who wrote (1158)1/27/1998 4:10:00 AM
From: Maurice Winn  Read Replies (1) of 3702
 
Davis, if you are on the committee winding it up, there was a little news item on Coulter, which as you know has an Iodine 131 labelled monoclonal antibody nearly ready for Non-Hodgkins Lymphoma treatment called Bexxar. The news item said: "Bexxar's unique efficacy/safety profile should result in worldwide sales of $400 million at peak," he said [analyst Peter Ginsberg].

I wonder whether he allowed any sales of Oncolym? Or Rituxan and other treatments coming up.

Maurice
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News